Meningococcal vaccine group B OMV (Novartis Pharma)

N/A

Report date: 2025/12/12 11:09:24

Base Information

Drug NameMeningococcal vaccine group B OMV (Novartis Pharma)
Drug Alias NameNew Zealand epidemic strain meningococcal B OMV vaccineB群脑膜炎球菌疫苗OMV - GlaxoSmithKline/NIPHNew Zealand candidate vaccine (NZ98/254)MeNZB
ClassificationVaccines > Biological material > Bacterial vaccineVaccines > Application > Prophylactic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsMeningococcal Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItalyChile
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma AgNorwegian Institute Of Public Health
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis Vaccines
Active IndicationsN/A
Inactive IndicationsMeningococcal Infections

Other Information

ATC CodeJ07AH06
Related LinksWikipedia